StratifiCare™ was founded in 2015 with the vision of empowering personalized medicine for tomorrow through our innovative diagnostic solutions. Our flagship product is the Severe Dengue Prediction Test –– Among 96M clinical Dengue infections yearly, up to 60% are hospitalized, yet only 0.02% die from hemorrhage. A world’s first, StratifiDen™ predicts the risk of severe Dengue complications accurately, and reduces hospitalization by 67%. With more than 50 years of in-depth experience in R&D and commercialization, StratifiCare™ has the internal know-how on identifying new biomarkers that can potentially help in the prognostication of other diseases that are of global concern.







For speaking, sponsorship and exhibition opportunities contact
Tel: +65 6322 2738